- Home
- JBDI vs AYTU Comparison
JBDI vs AYTU Comparison
Compare JBDI & AYTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JBDI
- AYTU
- Stock Information
- Founded
- JBDI 1983
- AYTU N/A
- Country
- JBDI Singapore
- AYTU United States
- Employees
- JBDI N/A
- AYTU N/A
- Industry
- JBDI
- AYTU Biotechnology: Pharmaceutical Preparations
- Sector
- JBDI
- AYTU Health Care
- Exchange
- JBDI Nasdaq
- AYTU Nasdaq
- Market Cap
- JBDI 28.7M
- AYTU 23.0M
- IPO Year
- JBDI 2024
- AYTU N/A
- Fundamental
- Price
- JBDI $1.02
- AYTU $2.09
- Analyst Decision
- JBDI
- AYTU Strong Buy
- Analyst Count
- JBDI 0
- AYTU 3
- Target Price
- JBDI N/A
- AYTU $9.17
- AVG Volume (30 Days)
- JBDI 59.2K
- AYTU 71.0K
- Earning Date
- JBDI 01-01-0001
- AYTU 11-13-2025
- Dividend Yield
- JBDI N/A
- AYTU N/A
- EPS Growth
- JBDI N/A
- AYTU N/A
- EPS
- JBDI N/A
- AYTU N/A
- Revenue
- JBDI $8,445,000.00
- AYTU $66,382,000.00
- Revenue This Year
- JBDI N/A
- AYTU N/A
- Revenue Next Year
- JBDI N/A
- AYTU $29.12
- P/E Ratio
- JBDI N/A
- AYTU N/A
- Revenue Growth
- JBDI N/A
- AYTU 1.84
- 52 Week Low
- JBDI $0.49
- AYTU $0.95
- 52 Week High
- JBDI $3.00
- AYTU $2.82
- Technical
- Relative Strength Index (RSI)
- JBDI 33.91
- AYTU 42.69
- Support Level
- JBDI $1.11
- AYTU $2.01
- Resistance Level
- JBDI $1.23
- AYTU $2.18
- Average True Range (ATR)
- JBDI 0.12
- AYTU 0.13
- MACD
- JBDI -0.03
- AYTU -0.02
- Stochastic Oscillator
- JBDI 4.54
- AYTU 54.90
About JBDI JBDI Holdings Limited Ordinary Shares
JBDI Holdings Ltd is a supplier of Reconditioned and new Containers in Singapore. Its products include Reconditioned and new steel drums, plastic drums, carboys and IBCs.
About AYTU Aytu BioPharma Inc.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.